Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab

Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been...

Full description

Saved in:
Bibliographic Details
Published in:Paediatric drugs 2023-11, Vol.25 (6), p.677-693
Main Authors: van Dijk, Yoni E., Rutjes, Niels W., Golebski, Korneliusz, Şahin, Havva, Hashimoto, Simone, Maitland-van der Zee, Anke-Hilse, Vijverberg, Susanne J. H.
Format: Article
Language:English
Subjects:
Allergens
Allergies
Asthma
Asthma in children
Biomarkers
Cytokines
Development and progression
Drug dosages
Drug therapy
Inflammation
Internal Medicine
Medicine
Medicine & Public Health
Monoclonal antibodies
Patients
Pediatric research
Pediatrics
Pharmacotherapy
Quality of life
Review
Review Article
Steroids
Teenagers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been developed to treat severe asthma, including monoclonal antibodies (biologics) targeting inflammatory mediators. Biologics that are currently approved to treat children (≥ 6 years of age) or adolescents (≥ 12 years of age) with severe asthma include: anti-immunoglobulin E (omalizumab), anti-interleukin (IL)-5 (mepolizumab), anti-IL5 receptor (benralizumab), anti-IL4/IL13 receptor (dupilumab), and antithymic stromal lymphopoietin (TSLP) (tezepelumab). However, access to these targeted treatments varies across countries and relies on few and crude indicators. There is a need for better treatment stratification to guide which children might benefit from these treatments. In this narrative review we will assess the most recent developments in the treatment of severe pediatric asthma, as well as potential biomarkers to assess treatment efficacy for this patient population.
ISSN:1174-5878
1179-2019
DOI:10.1007/s40272-023-00589-4